Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/26999
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCameron J.en
dc.contributor.authorPerera S.en
dc.contributor.authorAslam A.en
dc.contributor.authorStehli J.en
dc.contributor.authorKaye D.en
dc.contributor.authorLayland J.en
dc.contributor.authorNicholls S.J.en
dc.contributor.authorZaman S.en
dc.date.accessioned2021-05-14T09:01:58Zen
dc.date.available2021-05-14T09:01:58Zen
dc.date.copyright2021en
dc.date.created20210313en
dc.date.issued2021-03-13en
dc.identifier.citationHeart Lung and Circulation. 30 (1) (pp e37-e40), 2021. Date of Publication: January 2021.en
dc.identifier.issn1443-9506en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/26999en
dc.description.abstractBackground: Coronary artery disease (CAD) is the leading cause of mortality in Australian women. We identified gender differences in healthy lifestyle adherence in patients treated with percutaneous coronary intervention (PCI) for CAD. Method(s): Consecutive patients were prospectively recruited from three Australian institutions (2016-2017). The primary endpoint at 1 year follow-up was healthy lifestyle adherence defined as 3/3 of: a heart-healthy diet, being physically active and not smoking. Secondary endpoints included cardiac rehabilitation attendance, medication use and lipid levels. Result(s): From 729 participants (n=192, 26.3% women) 56% were adherent to all three lifestyle measures with no gender difference overall. Compared to men, women were less likely to smoke (7.7% versus 12.2%, p<0.001) to be physically active (61.5% versus 78.2%; p<0.0001), attend cardiac rehabilitation (58.2% versus 66.4%; p<0.045), and take statin therapy (85.4% versus 94.7%; p<0.0001). Female gender independently predicted physical inactivity (OR 2.41, 95% CI 1.57-3.68, p<0.001). Conclusion(s): Important gender differences exist in patients treated with PCI for CAD, namely, significant lower physical activity, cardiac rehabilitation attendance and statin use in women. These all represent key targets for gender-specific secondary prevention interventions.Copyright © 2020en
dc.languageenen
dc.languageEnglishen
dc.publisherElsevier Ltden
dc.relation.ispartofHeart Lung and Circulationen
dc.titleGender Differences in Healthy Lifestyle Adherence Following Percutaneous Coronary Intervention for Coronary Artery Disease.en
dc.typeArticleen
dc.identifier.doihttp://monash.idm.oclc.org/login?url=-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.hlc.2020.06.024en
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid32843294 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32843294]en
dc.identifier.source2007560886en
dc.identifier.institution(Perera, Aslam) Department of Medicine, Monash University, Melbourne, Vic, Australia (Stehli, Nicholls, Cameron, Zaman) Monash Cardiovascular Research Centre, Monash University, Melbourne, Vic, Australia (Stehli, Kaye) Department of Cardiology, Alfred Hospital, Melbourne, Vic, Australia (Kaye) Division of Cardiovascular, Baker Heart and Diabetes Institute, Melbourne, Vic, Australia (Layland) Department of Cardiology, Peninsula Health, Melbourne, Vic, Australia (Layland) Peninsula Clinical School, Monash University, Melbourne, Vic, Australia (Nicholls, Cameron, Zaman) MonashHeart, Monash Medical Centre, Melbourne, Vic, Australiaen
dc.description.addressS. Zaman, Monash Cardiovascular Research Centre, Monash Heart and Monash University, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria 3168, Australia. E-mail: sarah.zaman@monash.eduen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2021 Elsevier B.V., All rights reserved.en
dc.subect.keywordsCardiac rehabilitation Gender Health diet Healthy lifestyle Physical activityen
dc.identifier.authoremailZaman S.; sarah.zaman@monash.eduen
dc.description.grantOrganization: *Amgen* Organization No: 100002429 Country: United States Organization: *Anthera* Organization No: 100014929 Country: United States Organization: *AstraZeneca* Organization No: 100004325 Country: United Kingdom Organization: *Medicines Company* Organization No: 100015237 Country: United States Organization: *National Heart Foundation of Australia* Organization No: 501100001030 Country: Australia Organization: *Roche* Organization No: 100004337 Country: Switzerlanden
dc.identifier.affiliationext(Perera, Aslam) Department of Medicine, Monash University, Melbourne, Vic, Australia-
dc.identifier.affiliationext(Stehli, Nicholls, Cameron, Zaman) Monash Cardiovascular Research Centre, Monash University, Melbourne, Vic, Australia-
dc.identifier.affiliationext(Stehli, Kaye) Department of Cardiology, Alfred Hospital, Melbourne, Vic, Australia-
dc.identifier.affiliationext(Kaye) Division of Cardiovascular, Baker Heart and Diabetes Institute, Melbourne, Vic, Australia-
dc.identifier.affiliationext(Layland) Department of Cardiology, Peninsula Health, Melbourne, Vic, Australia-
dc.identifier.affiliationext(Layland) Peninsula Clinical School, Monash University, Melbourne, Vic, Australia-
dc.identifier.affiliationmh(Nicholls, Cameron, Zaman) MonashHeart, Monash Medical Centre, Melbourne, Vic, Australia-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptCardiology (MonashHeart & Victorian Heart Institute)-
crisitem.author.deptCardiology (MonashHeart & Victorian Heart Institute)-
Appears in Collections:Articles
Show simple item record

Page view(s)

50
checked on Oct 5, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.